Pharmaceutical

Menarini to enhance BPDCN detection with VisualDx’s link

Menarini Group has announced a partnership with VisualDx to enhance the diagnosis of individuals with BPDCN.

Mar 23, 2025 - 06:00
Menarini to enhance BPDCN detection with VisualDx’s link
Menarini Group has announced a partnership with VisualDx to enhance the diagnosis of individuals with BPDCN.
Read the original article

Tags:

Previous Article

How to manage regulatory complexities with clinical trial data

Next Article

Funding drought: how can biotech and biopharma keep trials running?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA advisers recommend approval of monoclonal antibody to protect newborns and young children from RSV

FDA advisers recommend approval of monoclonal antibody ...

Jun 8, 2023

Pneumagen raises £8 million for further study of intranasal antiviral

Pneumagen raises £8 million for further study of intran...

Jun 1, 2023

Microbiome company Enterome plans $108m raise to fund Phase II cancer trials

Microbiome company Enterome plans $108m raise to fund P...

Aug 26, 2023